Thymagen (Glutamyl-Tryptophan) is a synthetic dipeptide from the Khavinson bioregulator series registered in Russia for immunodeficiency conditions. It modulates T-cell differentiation and immune function.
1 independent Janoshik purity test cover Thymagen across 1 vendor.
Category: Immune / Bioregulator. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only (approved in Russia)
Modulates T-cell differentiation and normalizes CD4/CD8 ratios. Mimics thymic peptide activity to support immune system homeostasis, particularly in age-related thymic decline.
Safety considerations: Well-tolerated in Russian clinical use.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
| Vendor | Best tested purity |
|---|---|
| Peptide Gurus | 98.2% |
Thymagen is a Khavinson bioregulator dipeptide (Glu-Trp) researched for thymic function and immune system modulation, particularly in age-related immune decline (immunosenescence).
THYMAGEN has been studied for: Thymus support, Immune modulation, T-cell function, Immunosenescence support. Khavinson bioregulator; thymus/immune focus. Related to Thymalin and Vilon.
Dipeptide bioregulator that may stimulate thymic epithelial cell activity, supporting T-cell maturation and differentiation in the aging thymus.